Periodic Reporting for period 4 - STOP-COPD (PulseHaler™: A Novel Treatment Device for COPD.)
Période du rapport: 2021-08-01 au 2022-07-31
Respinova Ltd. has created the Pulsehaler™ technology for treating the core patho-physiology of COPD, “small airway disease”. Pulsehaler™ provides a stream of low pressure, high frequency, pressure pulses into the airway while the patient breathes on it. These pulses gently pry open the airways, while the pressure keeps them open. The frequency of the pulses also changes the viscosity of mucus making it more fluid and easier to expel. Pulsehaler™’s effectiveness was proven in a clinical study which showed that exercise capacity improved more than double the clinical gold standard difference, and more than 4x the reported improvement of drugs. Quality of life and lung function were also substantially improved.
The overall objectives of the project are to complete the design and manufacturing ramp up of the Pulsehaler, obtain regulatory approval in initial launch jurisdictions, and complete a clinical trial to drive adoption.